par Delhaye, Jean-Paul 
;Famaey, Jean Pierre
Référence Journal Belge de Rhumatologie et de Medicine Physique, 28, 1, page (14-22)
Publication Publié, 1973
;Famaey, Jean Pierre Référence Journal Belge de Rhumatologie et de Medicine Physique, 28, 1, page (14-22)
Publication Publié, 1973
Article révisé par les pairs
| Résumé : | From this experiment with pyrazinobutazone upon rheumatic upon rhumatismal pathology, carried out on 42 cases resistant to the usual therapy, i.e. indomethacine, ibuprofen, phenylbutazone and salicylate derivatives, it is concluded that this combined molecule does not lose the well known activity of phenylbutazone since 57% of the resistant cases were improved. Furthermore it has the advantage of being easily tolerated by various systems and especially by the digestive system, which is a significant advantage over the other pyrazolidine derivatives. The results, which arise from a careful investigation on a limited number of hospitalized patients, are supported by those which have been performed on more than 3,000 cases in daily therapy and which have been computerized. |
